Hot Investor Mandate: VC Firm Invests in US and Japan-Based Companies in All Life Science Sectors, With Strong Interest in Age-Related Diseases

14 Dec

A firm with offices in the US and Japan generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions.  
 
The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. DEFTA Partners prefers to invest in technologies at an early stage of development. 
 
The firm is interested in working with high quality management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment